Laboratorios Rovi’s Acquisition of CDMO plant in US provides attractive opportunity for profitable growth
Banc Sabadell | From the meeting held by the management of Laboratorios Rovi (ROVI) to explain the acquisition of a CDMO plant in the United States, we highlight the following messages: They do not expect the CDMO plant to be accretive to earnings for a couple of years, but they do expect a significant increase in profitability with the entry of new customers in the pre-filled syringe line. In any…